HC Wainwright & Co. Maintains Buy on Spruce Biosciences, Lowers Price Target to $150

Benzinga Newsdesk www.benzinga.com Negative 62.9%

Neg 62.9% Neu 0% Pos 0%

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Spruce Biosciences (NASDAQ:SPRB) with a Buy and lowers the price target from $200 to $150.